CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies

Deleted Journal, Journal Year: 2024, Volume and Issue: 2(2)

Published: April 1, 2024

Abstract T cells engineered to express chimeric antigen receptors (CARs) with specificity toward tumor have led promising outcomes in patients hematological malignancies. Nevertheless, the application of CAR‐T cell therapy solid tumors encounters several obstacles. These include heterogeneity and immune escape, exhaustion restricted infiltration into that affect therapeutic efficacy cells, as well “on‐target, off‐tumor” toxicities can lead severe even fatal adverse events. In recent years, clinical trials new approaches for made certain progress. Here, we update related summarize strategies aiming improve safety based on experimental studies.

Language: Английский

---

Tumor energy metabolism: implications for therapeutic targets

Molecular Biomedicine, Journal Year: 2024, Volume and Issue: 5(1)

Published: Nov. 29, 2024

Abstract Tumor energy metabolism plays a crucial role in the occurrence, progression, and drug resistance of tumors. The study tumor has gradually become an emerging field treatment. Recent studies have shown that epigenetic regulation is closely linked to metabolism, influencing metabolic remodeling biological traits cells. This review focuses on primary pathways explores therapeutic strategies target these pathways. It covers key areas such as glycolysis, Warburg effect, mitochondrial function, oxidative phosphorylation, adaptability Additionally, this article examines regulator SWI/SNF complex specifically its interactions with glucose, lipids, amino acids. Summarizing aimed at pathways, including inhibitors mitochondrial-targeted drugs, exploitation vulnerabilities, recent developments related complexes potential targets. clinical significance, challenges, future directions research are discussed, overcome resistance, combination therapy, application new technologies.

Language: Английский

---

Metabolomics at the tumor microenvironment interface: Decoding cellular conversations

Medicinal Research Reviews, Journal Year: 2023, Volume and Issue: 44(3), P. 1121 - 1146

Published: Dec. 26, 2023

Cancer heterogeneity remains a significant challenge for effective cancer treatments. Altered energetics is one of the hallmarks and influences tumor growth drug resistance. Studies have shown that exists within metabolic profile tumors, personalized-combination therapy with relevant interventions could improve patient response. Metabolomic studies are identifying novel biomarkers therapeutic targets improved treatment The spatial location elements in microenvironment becoming increasingly important understanding disease progression. evolution metabolomics analysis now allows scientists to deeply understand how metabolite distribution contributes biology. Recently, these techniques spatially resolved subcellular level. It has been proposed mapping outcomes by improving precision medicine, enabling earlier diagnosis intraoperatively margins. This review will discuss altered pathways contribute progression resistance explore current capabilities technologies be integrated into clinical practice outcomes.

Language: Английский

---

Succinate-Directed Approaches for Warburg Effect-Targeted Cancer Management, an Alternative to Current Treatments?

Cancers, Journal Year: 2023, Volume and Issue: 15(10), P. 2862 - 2862

Published: May 22, 2023

Approximately a century ago, Otto Warburg discovered that cancer cells use fermentative rather than oxidative metabolism even though the former is more inefficient in terms of energy production per molecule glucose. Cancer increase this presence oxygen, and process called aerobic glycolysis or effect. This alternative mainly characterized by higher glycolytic rates, which allow to obtain amounts total ATP, lactate, but there are also an activation protumoral signaling pathways generation molecules favor progression. One these succinate, Krebs cycle intermediate whose concentration increased considered oncometabolite. Several actions have been associated succinate its role several types has already described. Despite playing major cancer, so far, potential as target prevention treatment remained mostly unexplored, most previous Warburg-directed anticancer strategies focused on other intermediates. In review, we aim summarize succinate's functions discuss expression regulators therapy strategy.

Language: Английский

---

Online Monitoring and Stable Isotope Tracing of Cancer Associated Volatiles in Murine Model Captures Tumor Associated Markers in vivo

Analytica Chimica Acta, Journal Year: 2025, Volume and Issue: 1349, P. 343826 - 343826

Published: Feb. 20, 2025

The imperative need for early cancer detection, which is crucial improved survival rates in many severe cancers such as lung cancer, remains challenging due to the lack of reliable early-diagnosis technologies and robust biomarkers. To address this gap, innovative screening platforms are essential unveil chemical signatures its treatments. It established that oxidative tumor environment induces alterations host metabolic processes influences endogenous volatile synthesis. Despite efforts, consensus on unique markers detection has been elusive, partly genetic variation leading heterogeneity humans standardized procedures analytical analyses. In study, we utilized advanced secondary electrospray ionization (SESI) technique coupled with a high-resolution mass spectrometer (HRMS) non-invasively monitor volatiles pre-clinical mouse model real time. Our findings revealed 651 dysregulated features upon onset identified 36 correlated size. Endogenous tracing glucose metabolism highlighted γ-glutamyl cycle downstream pathway implicated driven by an imbalance glutathione reactive oxygen species (ROS) accumulation. Notably, our study unveiled changes associated gemcitabine cisplatin treatment, significantly abrogated growth vivo. Furthermore, 5-oxoproline metabolite indicative response treatment. conclusion, SESI-HRMS based analysis systematically explores provides novel non-invasive platform possess great potential real-time, confident, sensitive monitoring cancer.

Language: Английский

---

Targeted Therapy for the Management of Oral Potentially Malignant Disorders: A Systematic Review

Oral Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: March 6, 2025

This study aimed to integrate the available data published in literature identify and elucidate impact of targeted therapy for oral potentially malignant disorders (OPMDs). systematic review was conducted according guidelines Preferred Reporting Items Systematic Reviews Meta-analyses (PRISMA) 2020 statement. An electronic search across five databases with no publication date restriction January 2023 subsequently updated 2024. Eligibility criteria included studies focusing on therapies. Interventions that either did not align specific definition or failed meet precision-based treatment approaches were excluded from this review. Six clinical trials identified, all United States. The sample size ranged 12 150 subjects. Celecoxib, erlotinib, cetuximab, metformin, nivolumab employed as systemic therapies at varying doses. Some patients experienced disease progression statistically significant differences histological improvement rates increases. Certain reported treatment-related toxicity. findings do support use managing OPMDs, highlighting need additional further evaluate their efficacy.

Language: Английский

---

Advances in Sonodynamic Therapy: Focus on Ferroptosis

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Ferroptosis is a nonapoptotic form of cell death discovered in 2012. Noninvasive treatments regulating ferroptosis are important for wide range diseases. Among the noninvasive treatments, sonodynamic therapy (SDT) has become promising due to its strong tissue penetration and few side effects. In recent years, targeted drug delivery platforms constructed on basis SDT have provided an efficient mode regulation ferroptosis. Based latest research reports, this Perspective introduces basic mechanism influencing factors therapeutic effects, elucidates significance ferroptosis-targeted SDT, summarizes studies through different pathways. We also present innovative composite ultrasound-responsive platforms. Finally, brief summary outlook based current presented.

Language: Английский

---

ALDOB represents a potential prognostic biomarker for patients with clear cell renal cell carcinoma

Translational Andrology and Urology, Journal Year: 2023, Volume and Issue: 12(4), P. 549 - 571

Published: April 1, 2023

Previous studies have shown that aldolase B (ALDOB) might play controversial roles in multiple types of cancer, which could act as a cancer-promoting factor or cancer-inhibiting depending on the subtype cancer. However, role ALDOB clear cell renal carcinoma (ccRCC) patients has not been clearly elucidated. Therefore, this study aimed to comprehensively explore expression level, prognostic value, functional enrichment, immune infiltration, and N6-methyladenosine (m6A) modification ccRCC patients.A total 1,070 tissues 409 normal from Gene Expression Omnibus (GEO) database, The Cancer Genome Atlas (TCGA) ArrayExpress database were enrolled evaluate level value ccRCC. Kaplan-Meier survival curves Log-Rank test performed assess value. univariate multivariate Cox regression analysis used identify independent predictors patients. In addition, R version 4.2.0 with its suitable packages perform enrichment analysis, infiltration m6A methylation analysis. Statistical significance was set at P <0.05.The significantly down-regulated compared tissue, noticeably correlated T stage, M histologic grade revealed ALODB predictor overall (OS), disease-specific (DSS), progression-free (PFS) showed related genes mainly involved metabolism metabolic pathways substances, including glycolysis, gluconeogenesis, fatty acid degradation. Finally, suggested closely abundance cells stromal tumor microenvironment several regulators ccRCC.As potential biomarker for ccRCC, downregulation associated clinicopathological features, poor prognosis,

Language: Английский

---

SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis

Aging, Journal Year: 2023, Volume and Issue: unknown

Published: Aug. 10, 2023

Solute carrier family 1 member 5 (SLC1A5) is a of the solute (SLC) superfamily transporters and plays an important role in tumors as key transporter glutamine into cells. However, relationship between SLC1A5, which involved immune regulation, cell infiltration tumor microenvironment has not been elucidated, SLC1A5 ferroptosis rarely reported. Therefore, we comprehensively analyzed expression level across cancers compared it with that normal tissues. Then, was by single-cell analysis, gene set enrichment analysis (GSEA), Tumor Immune Estimation Resource (TIMER). Next, correlations immunotherapy response, immunomodulator expression, mutation burden (TMB) microsatellite instability (MSI) were evaluated. Finally, vitro experiments verified participates glioma cells to regulate progression. Our results indicated aberrantly expressed most cancer types closely associated prognosis. The GSEA showed activation processes related levels different types. Upon further investigation, found suppressor glioma, knockdown inhibited proliferation migration vitro. In conclusion, conducted pancancer demonstrated its prognostic biomarker patients explored potential biological functions.

Language: Английский

---

Aspartate in tumor microenvironment and beyond: Metabolic interactions and therapeutic perspectives

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: 1870(8), P. 167451 - 167451

Published: Aug. 5, 2024

Language: Английский

---